trial · primary record
pembrolizumab
Esophageal Squamous Cell Carcinoma (ESCC)
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 703 |
| Primary completion | 2026-06-26 |
| Primary endpoint | Event-free Survival (EFS) |
| Registry ID | NCT04210115 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:36.219Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04210115
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pembrolizumab · approval
- Pembrolizumab · compound